New Zealand - English - Medsafe (Medicines Safety Authority)

wilson foods limited - doxylamine succinate 25mg;   - liquid filled capsule - 25 mg - active: doxylamine succinate 25mg   excipient: amaranth butylated hydroxyanisole gelatin macrogol 400 patent blue v propylene glycol purified water sorbitol - temporary use in the relief of insomnia

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - doxylamine succinate, quantity: 25 mg - tablet, uncoated - excipient ingredients: purified talc; microcrystalline cellulose; croscarmellose sodium; povidone; calcium hydrogen phosphate dihydrate; magnesium stearate; pregelatinised maize starch - temporary relief of sleeplessness.

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - doxylamine succinate, quantity: 25 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate dihydrate; purified talc; pregelatinised maize starch; povidone; croscarmellose sodium; magnesium stearate - temporary relief of sleeplessness.

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - doxylamine succinate (unii: v9bi9b5yi2) (doxylamine - unii:95qb77jkpl), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z) - doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.   limitations of use doxylamine succinate and pyridoxine hydrochloride delayed-release tablet has not been studied in women with hyperemesis gravidarum.   doxylamine succinate and pyridoxine hydrochloride is contraindicated in women with any of the following conditions:   - known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation monoamine oxidase (mao) inhibitors intensify and prolong the adverse central nervous system effects of doxylamine succinate and pyridoxine hydrochloride [see drug interactions (7.1)].  risk summary doxylamine succinate and pyridoxine hydrochloride is intended for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. maternal risks a

United States - English - NLM (National Library of Medicine)

duchesnay usa, inc. - doxylamine succinate (unii: v9bi9b5yi2) (doxylamine - unii:95qb77jkpl), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z) - doxylamine succinate 10 mg - diclegis is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. limitations of use diclegis has not been studied in women with hyperemesis gravidarum. diclegis is contraindicated in women with any of the following conditions: risk summary diclegis is intended for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. maternal risks are discussed throughout the labeling. no increased risk for congenital malformations has been reported in epidemiologic studies in pregnant women. in the u.s. general population, the estimated background risks for major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively. data human data the combination of doxylamine succinate and pyridoxine hydrochloride has been the subject of many epidemiological studies (cohort, case control and meta-analyses) designed to detect possible teratogenicity. a meta-analysis of 16 coh

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - doxylamine succinate (unii: v9bi9b5yi2) (doxylamine - unii:95qb77jkpl), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z) - doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. limitations of use doxylamine succinate and pyridoxine hydrochloride delayed-release tablets have not been studied in women with hyperemesis gravidarum. doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are contraindicated in women with any of the following conditions: - known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation - monoamine oxidase (mao) inhibitors intensify and prolong the adverse central nervous system effects of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets [see drug interactions (7.1) ] . risk summary doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are intended for the treatment of nausea and vomiting of pregnanc

United States - English - NLM (National Library of Medicine)

analog pharma - doxylamine succinate (unii: v9bi9b5yi2) (doxylamine - unii:95qb77jkpl), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z) - doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. limitations of use doxylamine succinate and pyridoxine hydrochloride delayed-release tablets have not been studied in women with hyperemesis gravidarum. doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are contraindicated in women with any of the following conditions: - known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation - monoamine oxidase (mao) inhibitors intensify and prolong the adverse central nervous system effects of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets [see drug interactions (7.1)] . risk summary doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are intended for the treatment of nausea and vomiting of pregnancy

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - doxylamine succinate (unii: v9bi9b5yi2) (doxylamine - unii:95qb77jkpl), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z) - doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. limitations of use: doxylamine succinate and pyridoxine hydrochloride delayed-release tablets have not been studied in women with hyperemesis gravidarum. doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are contraindicated in women with any of the following conditions: doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are intended for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. maternal risks are discussed throughout the labeling. no increased risk for congenital malformations has been reported in epidemiologic studies in pregnant women. in the u.s. general population, the estimated background risks for major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectiv

Israel - English - Ministry of Health

cts chemical industries ltd, israel - doxylamine succinate - tablets - doxylamine succinate 25 mg - doxylamine - doxylamine - an aid to the relief of temporary sleep disturbance.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - doxylamine succinate, quantity: 25 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; maize starch; lactose monohydrate; magnesium stearate; purified water - for temporary relief of sleeplessness